Developer of the world’s first genetically modified probiotics, ZBiotics has secured $12 million in Series A funding round to meet the soaring consumer demand, support retail expansion, and drive research and development to bring more products to the market.
Co-founded in 2016 by Zachary Abbott and Stephen Lamb JD, the biotechnology startup develops genetically engineered probiotics designed to augment the functioning of human body systems, bringing new functionality to help the body handle everyday chemicals and contaminants.
The oversubscribed round was spearheaded by Springtide Capital and included participation from other investors, including Seamless Capital, Access Capital, Seaside Ventures, and Goat Rodeo Capital.
ZBiotics leverages modern biotechnology breakthroughs to help consumers engage in healthy living by developing genetically engineered probiotics for specific cases to help solve real-world problems.
Solving Modern-Day Problems
ZBiotics has developed a novel Pre-Alcohol Probiotic Drink, which mimics critical liver functions by breaking down toxic alcohol by-products such as acetaldehyde, helping alcohol consumers avoid the aftereffects of alcohol a day after alcohol consumption.
The oversubscribed round is a testament to the investors’ confidence in the ZBiotics team and their mission to commercialize a wide range of products that improve human health. The new capital will help the company develop and commercialize additional use-case products for the market, leveraging the innovative technology used to develop the novel Pre-Alcohol Probiotic Drink.